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Abstract
When testing association between rare variants and diseases, an efficient analytical approach involves considering a set of
variants in a genomic region as the unit of analysis. One factor complicating this approach is that the vast majority of rare
variants in practical applications are believed to represent background neutral variation. As a result, analyzing a single set
with all variants may not represent a powerful approach. Here, we propose two alternative strategies. In the first, we analyze
the subsets of rare variants exhaustively. In the second, we categorize variants selectively into two subsets: one in which
variants are overrepresented in cases, and the other in which variants are overrepresented in controls. When the proportion
of neutral variants is moderate to large we show, by simulations, that the both proposed strategies improve the statistical
power over methods analyzing a single set with total variants. When applied to a real sequencing association study, the
proposed methods consistently produce smaller p-values than their competitors. When applied to another real sequencing
dataset to study the difference of rare allele distributions between ethnic populations, the proposed methods detect the
overrepresentation of variants between the CHB (Chinese Han in Beijing) and YRI (Yoruba people of Ibadan) populations
with small p-values. Additional analyses suggest that there is no difference between the CHB and CHD (Chinese Han in
Denver) datasets, as expected. Finally, when applied to the CHB and JPT (Japanese people in Tokyo) populations, existing
methods fail to detect any difference, while it is detected by the proposed methods in several regions.
Citation: Zhang L, Pei Y-F, Li J, Papasian CJ, Deng H-W (2010) Efficient Utilization of Rare Variants for Detection of Disease-Related Genomic Regions. PLoS
ONE 5(12): e14288. doi:10.1371/journal.pone.0014288
Editor: Thorkild I. A. Sorensen, Institute of Preventive Medicine, Denmark
Received July 8, 2010; Accepted November 15, 2010; Published December 10, 2010
Copyright:  2010 Zhang et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: The investigators of this work benefited from the support of grants from the National Science Foundation of China, National Institutes of Health (R01
AR050496, R21 AG027110, R01 AG026564, P50 AR055081 and R21 AA015973), Huo Ying Dong Education Foundation, Hunan Province, and the Ministry of
Education of China. Computing support was partially provided by the High Performance Computing Cluster Center at Xi’an Jiaotong University. The funders had
no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: dengh@umkc.edu
Introduction
Genome-wide association studies (GWAS) have become popular
tools for identifying genetic susceptibility variants for complex diseases.
The success of this approach relies on the common disease-common
variant (CDCV) hypothesis, which presumes that phenotypic variation
of common diseases is explained by several common variants, each
with a relatively small effect [1,2,3]. For the purpose of association
mapping, hundreds of thousands of common variants across the
genome are genotyped and examined. In cases where causative
variants are not directly genotyped, association analysis can still be
achieved through indirect linkage disequilibrium (LD) mapping.
Despite the fruitful findings of recent GWAS [4], it is still
disappointing that only a small portion of phenotypic variation has
been attributed to common, identified genotypic variants for the
traits studied. Increasing sample size and/or genotyping greater
numbers of SNPs may help identify additional genetic suscepti-
bility variants. However, the potential additional yield of this
approach remains to be seen. Extensive studies have provided an
alternative to the CDCV hypothesis, termed the common disease-
rare variant (CDRV) hypothesis, that may also be important to the
etiology of complex diseases [5,6,7]. In the CDRV hypothesis,
phenotypic variation is assumed to be caused by multiple rare
variants [8,9,10,11,12,13,14]. Though individual mutation has a
low frequency, their gene-wise or pathway-wise aggregate
frequency could be substantially large, which makes it possible
for rare variants to be the cause of common diseases. It seems that
either the CDCV or CDRV hypotheses hold under certain
conditions, and that the etiology of complex disease reflects a
mixture of both hypotheses along with effects from other factors,
e.g., gene by gene interactions and environments.
When analyzing rare variants for association with phenotypes,
ordinary variant by variant methods have insufficient statistical
power due to allelic heterogeneity as well as the extreme rarity of
individual variants [15]. Alternatively, an efficient strategy has been
proposed that considers a set of rare variants in a genomic region as
the unit of analysis [15,16,17,18,19,20,21]. One complication that
arises in this group-wise strategy, however, is that not all rare
variants are potentially disease-causing; rather, a large proportion
are believed to represent background neutral variation. Obviously,
including rare variants that are irrelevant to phenotype into sets
would lead to a reduced signal to noise ratio, with a consequent
reduction in statistical power. Recent studies have suggested
focusing on non-synonymous variants in gene coding regions
[14,16]. Nonetheless, a remarkable proportion of non-synonymous
variants may still represent background population variation [8,22].
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analyzing the set with total variants may not represent an optimal
approach to performing powerful association tests.
In this study, aiming to improve statistical power of association
tests in the presence of neutral rare variants, we propose two
alternative strategies. We utilize simulations to investigate and
compare the performance of tests with different strategies under a
variety of conditions. Finally, we apply the proposed methods to
two real sequencing datasets to demonstrate their utilities.
Materials and Methods
Assume that there are nc affected individuals and nu normal
individuals, so that the total number of individuals is n=nc+nu.
Assume that a genomic region containing L rare variants
(MAF,0.01) is to be examined for association with the disease,
and genotype data gil (i=1,…, n, l=1,…, L) are available at all
variants for each individual. Here, the unit of analysis is the set of
variants rather than individual variants. Given the set of L
variants, a variety of grouping strategies exist. In the simplest way,
a single set, termed GT, is formed by including all variants. This
grouping strategy, referred to as total grouping, is widely adopted
by existing methods. We here describe two alternative grouping
strategies. In the first one (selective grouping), two sets are
selectively formed: one in which each variant has a greater
frequency in cases than in controls, and the other in which each
variant has a greater frequency in controls. We term the two
formed sets as GC and GU. In the second one (exhaustive grouping),
a total number of R=2
L-1 subsets (G1,…, GR) are formed
exhaustively. Below we outline two popular association tests and
their implementations with various grouping strategies.
Collapsing
Given a set of variants, the collapsing method [15] defines an
indicator variable for each individual i:
Xi~ 1 rare variants present
0 otherwise
 
:
Association is then examined on X between case and control
populations. The authors also proposed a combined multivariate
collapsing (CMC) method for analyzing rare and common variants
jointly. Since all variants to be investigated in this study are rare,
the CMC method is thus not applicable.
In the total grouping strategy, X is defined on the set GT. The
Fisher exact test (FET) is used to test the association and a two-
sided p-value is reported.
In the selective grouping strategy, X is defined and examined on the
two sets GC and GU separately. To compare with the total grouping
method fairly, we perform a two-sided test by examining whether rare
variants distribute differently between cases and controls. In order to
implement this test, the FET is applied to GC and GU separately, and
two one-sided p-values, termed pc and pu, are obtained. Note that the
FET here is merely a device measuring the strength of evidence against
the null hypothesis. A provisional index of significance, q, is calculated
as the minimum of the two nominal p-values obtained
q~min pc,pu ðÞ :
The significance of q is determined by Monte Carlo permutation
testing [17]. Specifically, we perform k replicates. In each replicate,
we permute the case/control status and perform the FET on the
permuted sample, from which the provisional index for the
replicate is obtained. A permutation p-value will be reported,
which is defined as k0/k, where k0 is the number of replicates that
have the indexes equal to or smaller than q.
In the exhaustive grouping strategy, X is defined on each of the
R formed subsets. The FET is applied to each subset separately,
and the smallest two-sided p-value over the R tests is taken as the
statistic.
Identifying the subset of variants that renders the smallest p-
value by testing subsets exhaustively, however, is computationally
demanding. When the number of variants involved is large, e.g.,
several dozens to hundreds, the exhaustive grouping strategy may
become computationally prohibitive. We note that some subsets
do not need to test. Taking a particular set G as an example, if one
of its subsets G-r, formed by removing a variant r from G, renders a
smaller p-value than that attained with G, then none of subsets of
G containing the variant r are likely to yield a smaller p-value than
attained with G-r, and consequently do not need to test. This
observation is driven by the fact that all variants in a set act
additively. We thus propose a simple and efficient algorithm to
reduce the number of tests. The algorithm is outlined below:
1) Set a candidate global set of variants G, which is specified by
the rare variants it contains, and is initialized to include all
variants. Set a global variable P for the minimal p-value,
which is initialized to be equal to the p-value rendered by
the initialized set G.
2) For each variant in G, remove it from G to form a subset
G21. Collapsing test is then examined on G21 and a two-
sided p-value is obtained. For m rare variants in G, there will
be m subsets each consisting of m-1 rare variants. Of the m
calculated p-values, the minimal one and the corresponding
subset are denoted as P’ and Gmin, respectively.
3) Set G=Gmin, and set P= P’i fP’,P.
4) Repeat steps 2) and 3) until the set G contains no variant.
The value P will be the p-value sought. Here, we adopt a step-
wise approach and exclude one variant in each repetition. In this
way, the number of subsets that need to be tested is reduced from
2
L-1 to L(L+1)/2 and the computation cost is reduced accordingly.
By running 100 simulated datasets each with 10 or 20 variants, we
observed that the algorithm found the correct minimal p-values in
all cases. Nonetheless, there is no guarantee for the accuracy, so we
will call this test the approximately optimal collapsing (AOC).
The significance of the test is again evaluated by Monte Carlo
permutation testing. Specifically, the case/control status is
permuted k times, and for each replicate the approximately
smallest p-value is calculated by the algorithm. A permutation p-
value is estimated and reported.
Group-wise weighted sum test (GWWS)
GWWS performs a one-sided test of whether there is an excess
of rare variants in a particular population, i.e., cases. In the total
grouping strategy, the GWWS method [17] is comprised of the
following steps for testing association:
1) For each variant l, calculate a weight ^ w wl~
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
n:ql 1{ql ðÞ
p
,
where ql~
mU
l z1
2nuz2
, where mU
l is the number of mutant
allele observed in the control population.
2) For each individual i, calculate a genetic score Xi~
X L
l~1
Iil
^ w wl
,
where Iil is the number of mutant allele at the lth variant.
Test Rare Variants for Disease
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calculated in 2).
4) The sum of rank of case individuals, termed S, is taken as the
statistic.
The significance of the test is again evaluated by permutation
testing. Specifically, in each of k replicates, case/control status is
permuted and the statistic is calculated. A normality approxima-
tion is used to estimate p-value. Denote the mean and standard
deviation of S over the k replicates as ^ m ms and ^ s ss. A normalized
statistic is given by
zs~
S{^ m ms
^ s ss
:
The statistic zs approximately follows a standard normal
distribution under the null hypothesis of no association, from
which a two-sided p-value will be evaluated and reported.
In the selective grouping strategy, GWWS is applied to GC and
GU separately, and two normality approximated p-values, p1 and
p2, are obtained. The final p-value ps is taken as the minimal of the
two p-values adjusted by the Bonferroni correction
ps~min 1, 2:min p1,p2 ðÞ ðÞ :
The exhaustive grouping strategy is applied to GWWS as well in
principle. However, the computation will be expensive since for
each of the R subsets, a series of permutations are required to
evaluate the significance. We thus do not implement the
exhaustive grouping strategy for GWWS.
There also exist several extensive methods that test association
between rare variants and diseases [14,18]. As the purpose of the
current study is to compare different grouping strategies rather
than different tests, we thus do not include these extensive methods
into analysis.
Simulation studies
Simulating allele frequency spectrum. In order to
investigate and compare the performance of various methods,
we conducted a series of simulation studies. We focused on the
European population and simulated sequence data by the use of a
four-parameter demographic model [16,23]. In this model, the
shape of European population history is assumed to start by a
constant ancestral population, followed by a population bottleneck
with a reduction in effective size, and then by an exponentially
expansion of the population until to the present. The four
parameters involved are the constant ancestral population size N1,
the bottleneck population size Nb, the duration of time T after the
bottleneck (measured by generation), and the population growth
rate c after the bottleneck. The detailed inference of the model was
described previously [16,24], and in the appendix S1, we outlined
the process. We formulated the demographic model in a likelihood
framework, and estimated the parameters of the model by
analyzing the real sequencing data produced by the ENCODE3
project [25]. The sequence data simulated from the model fitted
the real data well (Figure S1).
Using the inferred demographic model, we simulated full range
frequencies of sequence data to mimic a sequencing association
study. Specifically, we simulated sequence data for a gene with
1,000 nucleotides. The number of generated variants may vary,
but is approximately proportional to gene length.
Simulating phenotype. Both common and rare variants
may contribute to complex diseases. However, the usual way for
an association study is to analyze these two kinds of variants
separately. As the intention of this study is to analyze rare variants,
we thus use rare variants (MAF,1%) only to generate phenotype
and to test association. Though we focused on a case/control study
design, we simulated a pool of quantitatively phenotyped
individuals, from which we selected individuals with extreme
phenotypes as case/control subjects. This extreme sampling study
design is widely adopted in practical applications [10,14,16], and
its advantage over conventional sampling according to case/
control status is that enlarging the pool of phenotyped individuals
alone can increase statistical power to detect association, without
additional sequencing cost. Specifically, we simulated a pool of
50,000 phenotyped individuals, from which 500 individuals with
the lowest phenotypes and 500 with the highest were selected and
labeled as control and case subjects, respectively.
On simulating phenotype, a specified proportion of variants
were randomly selected as causative, while the remainder were
assumed to be neutral. Unless otherwise specified, we set the
proportion to be equal to 30%. To take into account the
uncertainty of phenotypic model under which multiple rare
variants jointly influence phenotype, we simulated the phenotype
under three phenotypic models.
Model 1: Causative alleles affected the phenotype equally
and in a cumulative way. Specifically, we defined a genetic
score for each individual i
xi~
X Lc
l~1
gil,
where Lc was the number of causative variants. Since
homozygous mutant genotypes are much rarer for rare
variants, we assumed an additive mode of inheritance and
encoded gil as 0, 1, or 2 for homozygous wild type,
heterozygous type, or homozygous mutant genotypes.
Model 2: The presence of one or more causative variants
caused the same shift of phenotypic mean. Specifically, the
genetic score was defined as an indicator
xi~ 1 causative variants present
0 otherwise
 
:
This model corresponds to the assumption adopted by the
collapsing method [15].
Model 3: Rarer variants were assumed to render larger
per-allele effects. Correspondingly, the genetic score was
defined as a weighted sum
xi~
X Lc
l~1
gil
wl
,
where wl~
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
pl 1{pl ðÞ
p
, where pl was the allele frequency
in the population. This model corresponded to the
assumption adopted by GWWS [17].
In table S1, we list the interaction of various phenotypic models
and genotypic encoding schemes by various tests. Note that other
Test Rare Variants for Disease
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which will not be investigated in this study.
Under each model, the phenotype was generated by the
ordinary regression equation
yi~mzbxizei,
where m was the grand mean; ei was assumed to follow a normal
distribution with mean zero. The coefficient b was determined by
the locus heritability h
2, which was defined as the proportion of
phenotypic variation explained by x,
h2~
b
2var x ðÞ
b
2var x ðÞ zvar e ðÞ
:
Evaluating performance. We evaluated the performance of
various tests described in this manuscript: collapsing, GWWS,
approximately optimal collapsing (AOC), selective collapsing
(SCollapsing), and selective GWWS (SGWWS). Statistical
properties, including type I error rate and power, of these tests
were investigated by simulation studies. Type I error rate was
evaluated by setting the locus heritability h
2 to zero, whereas
power was evaluated by setting it to a specific value. Unless
otherwise specified, the value of h
2 was set to 0.5% to simulate a
modest genetic effect. Both type I error rate and power were
estimated on 1,000 replicates, at the significance levels of 0.05 and
1.0E-3, respectively. For each replicate, 10,000 permutations will
be performed when needed. Both type I error rate and power were
defined as the proportion of replicates in which the p-value was
equal to or smaller than the significance threshold.
Simulation results
Type I error rates. While all other tests have correct type I
error rates that are close to the target level, SGWWS has a type I
error rate lower than the target level (table 1). This conservative
performance is caused by the fact that the Bonferroni correction is
used to adjust two dependent tests in SGWWS. We also estimated
type I error rates on naturally occurred sequence data of Chinese
Han in Beijing (CHB) and Yoruba people of Ibadan (YRI)
populations of the ENCODE3 project. To accomplish this, we
permuted all individuals’ population attribute, and then analyzed
the permuted datasets. Again, SGWWS has a conservative
performance while other tests are robust in all studied genomic
regions (table 2).
Power with the proportion of causative variants. In
figure 1, we estimated the power of various tests under different
proportions of causative variants. Obviously, all tests have
improved power with increasing proportion of causative
variants. At low proportion of causative variants, tests that are
Table 1. Type I error rates.
Gene length
Sequenced
size Test 500 1,000 1,500 2,000
500 Collapsing 3.4 4.0 3.8 3.9
SCollapsing 4.8 4.9 4.9 4.6
AOC 5.1 4.9 5.0 5.2
GWWS 5.1 5.1 4.8 4.8
SGWWS 2.6 3.6 3.8 4.2
1,000 Collapsing 3.8 4.7 4.3 4.1
SCollapsing 4.6 4.9 5.2 4.9
AOC 4.7 5.1 5.2 4.9
GWWS 4.9 5.0 5.0 5.5
SGWWS 2.7 3.5 4.1 4.4
2,000 Collapsing 4.3 4.7 4.4 4.0
SCollapsing 4.8 5.3 4.7 5.1
AOC 4.9 5.0 4.8 5.2
GWWS 5.0 5.0 5.1 4.9
SGWWS 2.8 3.7 4.0 4.3
Notes: A total number of 50,000 quantitatively phenotyped individuals were
simulated, of which 500, 1,000, and 2,000 individuals with equally numbers of
highest and lowest phenotypes were selected as case and control subjects. The
gene length varied from 500 to 2,000 nucleotides. Type I error rates were
estimated on 1,000 replicates at the significance level 0.05. For each replicate,
10,000 permutations were performed. Abbreviation: Collapsing, the collapsing
method proposed by Li and Leal [15]; SCollapsing, the collapsing method with
selective grouping strategy; AOC, the approximately optimal collapsing; GWWS,
the group-wise weighted sum method proposed by Madsen and Browning [17];
SGWWS, the GWWS method with selective grouping strategy.
doi:10.1371/journal.pone.0014288.t001
Table 2. Type I error rates on the ENCODE3 datasets.
Test
Region #variants Collapsing SCollapsing AOC GWWS SGWWS
ENr221 90 4.8 5.0 5.1 5.1 3.9
ENm010 152 3.9 4.8 4.9 4.9 4.1
ENr321 141 4.8 5.1 5.0 4.8 4.0
ENr232 127 5.1 4.9 4.8 4.5 4.6
ENr123 76 4.7 4.9 5.2 4.8 4.5
ENr213 126 5.2 5.2 4.6 5.1 3.9
ENr133 102 4.7 4.6 4.8 5.2 4.5
Notes: Seven ENCODE3 regions are available for analysis. In each region, we tested the overrepresentation of rare variants between the CHB (90 individuals) and the YRI
populations (120 individuals). The MAF cutoff 1% was applied. For each dataset, the total number of variants was given. To evaluate the type I error rate, we permuted
each individual’s population attribute and analyzed the permuted datasets. Type I error rates were estimated on 1,000 replicates at the significance level 0.05. See notes
for table 1 for abbreviation detail.
doi:10.1371/journal.pone.0014288.t002
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power over tests on grouping all variants. For example, at
proportion 0.1, the power of AOC, SCollapsing and SGWWS
under model 1 are 64.1%, 29.8% and 29.7%, while that of
Collapsing and GWWS are only 7.4% and 10.5%, respectively.
When the proportion increases, the magnitude of power
improvement gets minor. Finally when at high proportion, tests
with grouping all variants instead have higher power. This
simulation clearly shows that when the proportion of causative
variants is low to modest, the proposed alternative grouping
strategies are advantageous.
Power with gene heritability. We then evaluated the power
of various tests under different gene heritabilities. All tests have
improved power with increasing heritability (figure 2). Among
tests, AOC has the highest power, followed by SGWWS,
SCollapsing, GWWS, and Collapsing. Phenotypic model has
limited influence in relative performance of tests, but all tests have
lower power in model 3 than in models 1 and 2. AOC, SGWWS,
and SCollapsing have power around 75%, 70% and 60%
respectively to detect gene with 0.5% heritability in models 1
and 2, while that of GWWS and Collapsing are 45% and 35%.
When the heritability finally increases to 1.0%, tests with
alternative groupings have nearly 100% power in models 1 and
2, and over 80% in model 3. GWWS has approximately 90%
power in models 1 and 2, and in model 3 its power is around 80%.
While the power of Collapsing in models 1 and 2 maintains at
75%, it is only 60% in model 3.
Power with gene length. Fixing the proportion of causative
variants and gene heritability, we then estimated the effect of gene
length on power estimate. As shown in figure 3, all tests have
decreased power with increased gene length in all phenotypic
models. Among tests, tests with alternative grouping strategies
generally have higher power over GWWS and Collapsing.
Power with phenotyped sample size. Table 3 lists the
power of various tests with different numbers of phenotyped
individuals. Obviously, enlarging the pool of phenotyped
individuals alone can substantially improve the power. Again,
tests with alternative groupings are more powerful than that with
grouping all variants.
Computation time. The computation time was determined
by running a dataset containing 500/500 individuals and a gene
with 1,000 nucleotides on a desktop computer with an Intel
2.40 GHz Core 2 Duo CPU E4600. All tests but AOC complete
the computation within seconds for 10,000 permutations; AOC
takes approximately one hour with 1,000 permutations. This is
because the time complexity for AOC is quadratic to the number
of variants while it is linear for other tests.
Application I
As a first application, we re-analyzed the sequence data
produced by Cohen et al. [11]. In their study, in order to examine
the association of the candidate gene NPC1L1 with low density
lipoprotein cholesterol (LDL-C) level, the authors sequenced the
gene in an initial sample with two groups each comprising 128
individuals with lowest and highest ratios of campesterol to
lathosterol (Ca:L ratio) from the Dallas Heart Study (DHS,
Sample 1). A total number of 16 rare non-synonymous variants
were discovered, 13 of which are exclusive in cases and 3 exclusive
in controls.
To validate their findings, the authors sequenced the same gene
in a second sample comprising the same numbers of individuals
again from the DHS with the next lowest and highest Ca:L ratios
(Sample 2). A total number of 12 rare non-synonymous variants
were discovered, 10 of which are exclusive in cases and 2 exclusive
in controls.
In addition to analyzing the two samples separately, we
combined them and analyzed the total rare variants together
(Combined).
Application I results
As shown in table 4, all tests have the ability to detect the
association at the significance level 0.05, but tests with the
proposed grouping strategies produce smaller p-values than those
with grouping all variants. For example, when applied to the
combined sample, AOC, SCollapsing, and SGWWS have p-values
3.90E-5, 3.68E-5, and 5.86E-6, while that of Collapsing and
GWWS are 1.23E-4 and 1.00E-4, respectively.
Application II
As a second application, we analyzed the sequence datasets
produced by the ENCODE3 project [25]. In the ENCODE3
project ten 100 kb genomic regions were sequenced in 11
populations. We selected four populations: CHB, Japanese people
in Tokyo (JPT), Chinese Han in Denver (CHD), and YRI for
analysis, of which 90, 97, 30, and 120 individuals were sequenced
respectively. Data on seven genomic regions were available for
analysis. Genotype data (released on March 14
th 2008) were
downloaded from the project ftp site (ftp://ftp.hgsc.bcm.tmc.edu/
pub/data/HapMap3-ENCODE/ENCODE3//ENCODE3v1/).
Variants that failed to be called in all individuals were excluded.
Within each region, we examined the difference of rare allelic
distributions between CHB and each of the other three
populations. This is equivalent to an association study by labeling
individuals from one population as cases and that from the other
population as controls [17]. A number of 10,000,000 permutations
were replicated. Since GWWS, unlike the other encoding
schemes, can only test whether there is an enrichment of rare
variants in a particular population, we perform the test twice and
report the minimal of the two p-values.
Application II results
We first tested the overrepresentation of rare variants between
the CHB and YRI populations. The results from the proposed
tests clearly show that rare allelic distribution between the two
populations is significantly different (table 5). Among the tests,
SCollapsing produces the smallest p-values, followed by AOC and
SGWWS, and GWWS, and at last Collapsing. At some regions, p-
values produced by the proposed tests are extremely small. For
example, when analyzing the region ENr213, SCollapsing, AOC,
and SGWWS have p-values 1.00E-7, 1.00E-7, and 1.22E-7, while
that of GWWS and Collapsing are 3.72E-4 and 1.27E-3. Though
GWWS and Collapsing have the ability to detect the difference in
Figure 1. Power with the proportion of causative variants. A total of 50,000 phenotyped individuals were simulated, of which 500 with lowest
and 500 with highest phenotypes were selected as control and case subjects, respectively. A gene with 1,000 nucleotides was simulated, and the
proportion of causative variants varied from 0.1 to 1.0. The gene was assumed to explain a proportion of 0.5% of phenotypic variation. Three
phenotypic models were simulated. In model 1, causative alleles affected the phenotype equally and in a cumulative way. In model 2, the presence of
one or more causative variants caused the same shift of phenotypic mean. In model 3, rarer causative variants had a larger per-allele effect and
variants contributed to the phenotype in a cumulative way. Power was estimated on 1,000 replicates at the significance level 1.0E-3.
doi:10.1371/journal.pone.0014288.g001
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PLoS ONE | www.plosone.org 6 December 2010 | Volume 5 | Issue 12 | e14288Figure 2. Power with gene heritability. A total of 50,000 phenotyped individuals were simulated, of which 500 with lowest and 500 with highest
phenotypes were selected as control and case subjects, respectively. A gene with 1,000 nucleotides was simulated, and the proportion of causative
variants was set to 30%. Three phenotypic models were simulated. Under each model, the gene heritability varied from 0.1% to 1.0%. Power was
estimated on 1,000 replicates at the significance level 1.0E-3.
doi:10.1371/journal.pone.0014288.g002
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PLoS ONE | www.plosone.org 7 December 2010 | Volume 5 | Issue 12 | e14288Figure 3. Power with gene length. A total of 50,000 phenotyped individuals were simulated, of which 500 with lowest and 500 with highest
phenotypes were selected as control and case subjects, respectively. The proportion of causative variants was set to 30%, and the gene heritability
was set to 0.5%. Three phenotypic models were simulated. Under each model, the gene length varied from 500 to 2,000 nucleotides. Power was
estimated on 1,000 replicates at the significance level 1.0E-3.
doi:10.1371/journal.pone.0014288.g003
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even at the level 0.05.
We then analyzed the CHB and JPT populations, as listed in
table 6. Collapsing and GWWS report none regions to exhibit
difference at the significance level 0.05. In contrast, SCollapsing
detects four regions that have different distributions between the
two populations. Taking two additional regions reported by
SGWWS into account, of 7 regions there are 6 are detected by the
proposed tests to exhibit difference. These findings clearly
demonstrate the ability of the proposed tests in detecting tiny
effects that the existing methods fail to detect.
Finally, we analyzed the CHB and CHD datasets. As
individuals in these two datasets are from the same population,
it is expected that no difference exists between these two
datasets. As expected, none region except ENr213 shows any
significant difference by any test (table 7). SCollapsing and AOC
detect that rare variants in the region ENr213 may distribute
differently.
Discussion
In this study, in order to improve statistical power of testing
disease-associated rare variants, we proposed two alternative
grouping strategies to the strategy of grouping total variants. When
the proportion of neutral variants is moderate to large we show, by
simulations, that both the proposed grouping strategies improve
power. The applications to two real sequencing studies demon-
strate the utilities of the proposed methods.
Currently, GWAS is the most widely used approach for
identifying genes that are associated with complex diseases. In a
typical GWAS, causative variants are usually not observable;
instead, their effects are detected through nearby SNP markers,
with the power depending on the strength of linkage disequilib-
rium (LD) between them. Thus, the pattern of LD underpins the
validity and success of this indirect association approach. In
sequencing studies, on the other hand, the observed genetic
variants are usually hypothesized to be directly functional and are
of primary interest. Furthermore, the level of LD between rare and
nearby variants is usually extremely low [8]. Thus, direct
association mapping is preferable for analyzing rare variants.
Due to their low coverage, current genotyping platforms are
inefficient for discovering rare variants. Fortunately, advances in
the development of sequencing technologies [26,27], and the
recently launched 1000 genomes project [28], make sequencing
huge numbers of rare variants across the entire genome a reality in
the coming years.
The strategy of grouping rare variants has proven to be a
powerful approach for analyzing rare variants. If potential
causative variants account for the vast majority of variants, the
utility of grouping total variants should be adequate, but this is
unlikely to be the majority of cases in practical applications. A
recent large-scale X chromosome sequencing study suggests that a
large quantity of mis-sense substitutions in candidate genes exist
indistinguishably in both of the case and control populations [8],
indicating that a considerable proportion of mis-sense substitutions
are actually background variation. Under such circumstances, the
issue of distinguishing truly functional variants from background
neutral variations is a major analytical challenge to this approach.
Alternative grouping strategies, e.g., the two proposed in this
manuscript, are warranted. The analyses of real sequencing
datasets verify the superiority of the proposed methods over the
existing methods.
Table 3. Power with phenotyed sample sizes.
Phenotyped Sample Size
Phenotypic
Model Test 25,000 50,000 100,000
Model 1 Collapsing 0.23 0.35 0.45
SCollapsing 0.42 0.57 0.72
AOC 0.64 0.73 0.85
GWWS 0.30 0.45 0.56
SGWWS 0.54 0.69 0.81
Model 2 Collapsing 0.28 0.37 0.46
SCollapsing 0.45 0.61 0.73
AOC 0.56 0.76 0.85
GWWS 0.30 0.43 0.54
SGWWS 0.55 0.69 0.80
Model 3 Collapsing 0.14 0.20 0.29
SCollapsing 0.17 0.25 0.39
AOC 0.34 0.50 0.69
GWWS 0.20 0.31 0.44
SGWWS 0.30 0.41 0.58
Notes: The number of phenotyped individuals varied from 25,000 to 100,000. A
gene with 1,000 nucleotides was simulated, and three phenotypic models were
considered. Thirty percent of the produced variants were assumed to be
causative. The gene was assumed to explain 0.5% of the total phenotypic
variation. Power was estimated on 1,000 replicates at the significance level 1.0E-
3. See notes for table 1 for abbreviation detail.
doi:10.1371/journal.pone.0014288.t003
Table 4. Analyses of the sequence data produced by Cohen et al. [11].
Test
Sample Collapsing SCollapsing AOC GWWS SGWWS
Sample 1 3.16E-3 1.29E-3 1.60E-3 1.96E-3 4.31E-4
Sample 2 0.03 0.01 0.02 0.02 0.02
Combined 1.23E-4 3.68E-5 3.90E-5 1.00E-4 5.86E-6
Notes: The candidate gene NPC1L1 was sequenced in two samples. The first sample (Sample 1) was comprised of 128 individuals with highest ratios of campesterol to
lathosterol (Ca:L ratio) and 128 individuals with lowest ratios from the Dallas Heart Study (DHS). A total number of 16 non-synonymous variants were analyzed, 13 of
which are exclusive in cases and 3 exclusive in controls. The second sample (Sample 2) was comprised of the same number of individuals with the next highest and
lowest Ca:L ratios from the DHS. A total number of 12 non-synonymous variants were analyzed, 10 of which are exclusive in cases and 2 exclusive in controls. The
combined sample was formed by combining the two samples together. See notes for table 1 for abbreviation detail.
doi:10.1371/journal.pone.0014288.t004
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straightforward. In the first strategy of exhaustive grouping, by
testing all subsets, we aim to identify the subset with the clearest
signal. This strategy has been previously adopted in the literature
of haplotype based association [29] and of gene by gene
interaction studies [30]. In the second strategy of selective
grouping, it is intuitive that only those variants that are
overrepresented in one population could be statistically judged
as the risk allele for that population. This strategy, by excluding
non-informative rare variants from grouping, is expected to
improve statistical power when neutral variants comprise a
substantial large proportion of the total variants. We have
demonstrated, through simulations, that our proposed alternative
grouping methods partially solve the problem created by the total
grouping strategy which ignores the noise of background
population variation.
In the selective grouping, two sets Gc and Gu are formed. While
the Gc part may represent potentially causative variants, Gu part is
believed to represent background variation. However, including
Gu part into analysis could provide a two-sided test of whether
variants are associated with the phenotype rather than a one-
sided test of whether variants enrich in a particular population,
i.e., cases. This broader hypothesis makes it comparable to
compare between tests with various grouping strategies. The Gu
part could also be informative in the presence of beneficial
mutations, i.e., those mutations which reduce the risk to the
disease.
For a set of L rare variants, the time complexity for methods
with exhaustive grouping is O(2
L), while that for methods without
exhaustive groupings is only O(1). The computation time for
exhaustive grouping increases exponentially with the number of
variants, and is prohibitive for analyzing several dozens to
hundreds of variants. To circumvent this computation issue, we
have developed a step-wise algorithm to search for the minimal p-
value over the set, the time complexity of which is O(L
2).
Alternatively, the proposed selective grouping method is compu-
tationally effective, without additional increase in time complexity
compared to total grouping. In practical applications where huge
numbers of rare variants may be involved, e.g., exome studies, the
selective grouping method is thus recommended, and exhaustive
grouping should be regarded as a tool to verify significant results.
Our simulations show that statistical power of testing association
decreases as gene elongates, though the proportion of causative
variants is fixed. To understand this phenomenon, gene
heritability must be taken into consideration, which was always
fixed at 0.5% as gene length varied in our simulations. Longer
gene introduces more noise, which tends to reduce power. Though
meanwhile it introduces a greater number of causative variants as
well, the phenotypic effect of these causative variants, that is, gene
heritability, remains unchanged. In other words, the per-variant
Table 5. Analyses of the ENCODE3 datasets for the CHB and YRI populations.
Test
Region #variants Collapsing SCollapsing AOC GWWS SGWWS
ENr221 90(31/59) 0.11 5.37E-6 9.00E-4 0.02 1.53E-4
ENm010 152(56/96) 0.58 2.21E-6 1.10E-3 0.04 1.22E-3
ENr321 141(53/88) 0.20 2.04E-7 1.00E-7 0.02 6.25E-6
ENr232 127(59/68) 0.89 6.63E-4 0.01 0.34 0.03
ENr123 76(27/49) 1.00 8.10E-4 0.02 0.50 0.03
ENr213 126(35/91) 1.27E-3 1.00E-7 1.00E-7 3.72E-4 1.22E-7
ENr133 102(37/65) 0.03 1.63E-5 8.05E-4 0.03 1.98E-4
Notes: We tested the overrepresentation of rare variants between the CHB (90 individuals) and YRI populations (120 individuals). For each region, the total number of
variants was given, followed by the number of variants that have larger frequencies in the CHB population (the first number in the parenthesis) and the number of
variants that have larger frequencies in the YRI population (the second number in the parenthesis). See notes for table 1 for abbreviation detail.
doi:10.1371/journal.pone.0014288.t005
Table 6. Analyses of the ENCODE3 datasets for the CHB and JPT populations.
Test
Region #variants Collapsing SCollapsing AOC GWWS SGWWS
ENr221 55(33/22) 0.26 0.15 0.07 0.19 0.05
ENm010 122(63/59) 0.76 0.04 0.24 0.34 0.15
ENr321 108(54/54) 0.77 5.73E-3 0.06 0.35 0.12
ENr232 104(69/35) 0.07 0.79 0.04 0.09 0.05
ENr123 63(35/28) 0.43 0.05 0.07 0.42 0.08
ENr213 81(38/43) 1.00 0.02 0.12 0.53 0.14
ENr133 63(33/30) 0.88 0.26 0.43 0.74 0.48
Notes: We tested the overrepresentation of rare variants between the CHB (90 individuals) and JPT populations (97 individuals). For each region, the total number of
variants was given, followed by the number of variants that have larger frequencies in the CHB population (the first number in the parenthesis) and the number of
variants that have larger frequencies in the JPT population (the second number in the parenthesis). See notes for table 1 for abbreviation detail.
doi:10.1371/journal.pone.0014288.t006
Test Rare Variants for Disease
PLoS ONE | www.plosone.org 10 December 2010 | Volume 5 | Issue 12 | e14288effect gets smaller with longer gene. Consequently, though signal-
to-noise ratio is fixed, the power would still tend to decrease as
gene elongates. This trend of power with gene length (or number
of variants) was also observed in previous studies [16,17].
The problem of population stratification by admixture of
different ethnic populations is a serious concern for association
studies [31,32,33] with both common and rare variants. Strictly
matched case-control pairs, e.g., affected case and its unaffected
sib, provide the most reliable guard against population stratifica-
tion. However, recruiting such samples is costly and difficult. For
association studies with common variants, spurious associations
can be controlled at the population level, towards which a variety
of approaches have been proposed [34,35,36]. For studies with
rare variants, on the other hand, little is known on the magnitude
of the impact of population stratification and on the performance
of existing correction approaches. We therefore restricted our
analyses to homogeneous populations, but the issue of population
stratification deserves further investigation.
In this study, we used a MAF cutoff 0.01 for a rare variant, but
other cutoffs could be used as well. In our simulation studies we
show that our proposed strategies could improve power when the
proportion of causative variants is low to modest, while the power
improvement is little or even negative when the proportion is
large. Thus, the proper test for a particular study should be chosen
according to the knowledge on the distribution of potential
causative variants. In most practical applications where there is no
knowledge on the potential causative variants, cross-validation of
the results from various tests is warranted.
Statistical methods derived not from classical statistical theories,
like the ones proposed in this manuscript, may be biased. The
biasness could be evaluated by simulation studies, which showed
that on one hand, the power rate of the proposed tests was equal to
the significance level under the null hypothesis. On the other
hand, the power rate was an increasing function of locus effect
and/or proportion of causative variants so that it would excess the
significance level under the alternative hypothesis. These two
aspects of power function under the null and alternative hypothesis
together indicated that the proposed tests were unbiased.
Despite the methods proposed in this manuscript, analyzing
associations between rare variants and complex diseases remains
quite challenging. When neutral variants comprise a large
proportion of the total variants, the selective grouping is still
low-powered, and more specialized approaches are expected to
emerge. In the study of Tarpey et al. [8], three new genes were
identified for mental retardation. From a statistical point of view,
however, none of the three genes were statistically significant.
Rather, the authors compared amino acids with their orthologs
from other species, and ranked the importance of amino acids
according to their conservation scores. This approach holds
promise for further methodological development and might
provide another tool for performing powerful association tests by
considering biological or evolutionary information.
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Appendix S1 The appendix that describes the process of
demographic model.
Found at: doi:10.1371/journal.pone.0014288.s001 (0.09 MB
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Figure S1 Fitness of simulated variants to experimental variants.
Legend: Sequence data of European population from the
ENCODE3 project were used to estimate demographic model.
Data of 119 individuals (238 haplotypes) on 7 genomic regions
were available. After filtering out variants with missing genotypes,
a total of 83 gene-coding variants and 953 non-coding (neutral)
variants were used for analysis, corresponding to 5.3 kb and
66.7 kb sequence sites respectively. A: the fitness of simulated
allele frequencies to experimental data on neutral variants; B: the
fitness of simulated allele frequencies to experimental data on
gene-coding variants.
Found at: doi:10.1371/journal.pone.0014288.s002 (0.27 MB TIF)
Table S1 Phenotypic models versus encoding schemes
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Table 7. Analyses of the ENCODE3 datasets for the CHB and CHD populations.
Test
Region #variants Collapsing SCollapsing AOC GWWS SGWWS
ENr221 53(37/16) 1.00 0.92 0.44 0.92 0.99
ENm010 102(67/35) 0.67 0.12 0.11 0.36 0.42
ENr321 101(64/37) 1.00 0.41 0.83 0.32 0.49
ENr232 100(78/22) 0.29 0.59 0.66 0.38 0.43
ENr123 51(39/12) 0.14 0.65 0.68 0.11 0.36
ENr213 88(60/28) 0.29 4.32E-3 0.01 0.19 0.10
ENr133 45(32/13) 0.83 0.78 0.62 0.92 0.88
Notes: We tested the overrepresentation of rare variants between the CHB (90 individuals) and CHD populations (30 individuals). For each dataset, the total number of
variants was given, followed by the number of variants that have larger frequencies in the CHB population (the first number in the parenthesis) and the number of
variants that have larger frequencies in the CHD population (the second number in the parenthesis). See notes for table 1 for abbreviation detail.
doi:10.1371/journal.pone.0014288.t007
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